IP Library › Granted Patent US 10,463,615
Granted Patent B2
US 10,463,615 · App. 15/632,562 · Granted Nov 5, 2019

Circulation of components during microfluidization and/or homogenization of emulsions

Inventors: Harald Rueckl (Alsfeld, DE); Hanno Scheffczik (Marburg, DE); Barbara Santry (Meath, IE)
Assignee: NOVARTIS AG
A61K9/1075A61K9/107A61K39/39B01F3/0807B01F5/0661B01F7/00766B01F13/1016A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,463,615
App. No.
15/632,562
Granted
Nov 5, 2019
Kind
B2
Abstract

An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.

Claims (11)

1. A method for preparing a vaccine kit comprising:

1) preparing an emulsion by a method comprising the step of:

(a) forming a first emulsion having a first average oil droplet size; and

(b) microfluidizing the first emulsion having a first average oil droplet size to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size, wherein the second emulsion is formed by (a) at least one type I circulation of transferring the second emulsion components between a first container and a microfluidizer and (b) at least one type II circulation of transferring the second emulsion components from a first emulsion container, through a first microfluidization device to a second emulsion container, and then again through the same microfluidization device; and

2) packaging the emulsion into a kit as a kit component together with an antigen component.

2. The method of claim 1 , wherein the kit components are in separate vials.

3. The method of claim 2 , wherein the vials are made from borosilicate glass.

4. The method of claim 1 , wherein the adjuvant is a bulk adjuvant and the method comprises extracting unit doses from the bulk adjuvant for packaging as kit components.

5. The method of claim 1 , wherein the antigen is an influenza virus antigen.

6. The method of claim 5 , wherein the combination of the emulsion and the antigen forms a vaccine composition and wherein the vaccine composition includes about 15 μg, about 10 μg, about 7.5 μg, about 5 μg, about 3.8 μg, about 1.9 μg, about 1.5 μg of hemagglutinin per influenza virus strain.

7. The method of claim 5 , wherein the combination of the emulsion and the antigen forms a vaccine composition and wherein the vaccine composition includes a thimerosal or 2-phenoxyethanol preservative.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 069642/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2017
From: RUECKL, HARALD; SCHEFFCZIK, HANNO; SANTRY, BARBARA
To: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Reel/Frame 042812/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2017
From: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
To: NOVARTIS AG
Reel/Frame 042812/0406 →
Continuity (4)
Continuation 14478864 · Sep 5, 2014
Continuation 13513564
Provisional Application 61283518 · Dec 3, 2009
Related Publication 20180055769A1 · Mar 1, 2018